Costs and effectiveness of neonatal male circumcision

Archives of Pediatrics and Adolescent Medicine

Volumn 166, Issue 10, 2012, Pages 910-918

  Kacker, Seema ^a   Frick, Kevin D ^b   Gaydos, Charlotte A ^a,b   Tobian, Aaron A R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CIRCUMCISION; CLINICAL EFFECTIVENESS; FEMALE; HEALTH CARE COST; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2 INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PAPILLOMAVIRUS INFECTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; TRICHOMONIASIS; UNITED STATES; URINARY TRACT INFECTION; VAGINITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CIRCUMCISION, MALE; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; INFANT, NEWBORN; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, ECONOMIC; MONTE CARLO METHOD; PREVALENCE; SEXUALLY TRANSMITTED DISEASES; UNITED STATES; YOUNG ADULT;

EID: 84867136944     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2012.1440     Document Type: Article

References (67)

1. Tobian AA, Gray RH. The medical benefits of male circumcision. JAMA. 2011;306(13):1479-1480.
2. Xu F, Markowitz LE, Sternberg MR, Aral SO. Prevalence of circumcision and herpes simplex virus type 2 infection in men in the United States: the National Health and Nutrition Examination Survey (NHANES), 1999-2004. Sex Transm Dis. 2007;34(7):479-484. (Pubitemid 46987955)
3. Sansom SL, Prabhu VS, Hutchinson AB, et al. Cost-effectiveness of newborn circumcision in reducing lifetime HIV risk among U.S. males. PLoS One. 2010;5(1):e8723.
4. Clark SJ, Kilmarx PH, Kretsinger K. Coverage of newborn and adult male circumcision varies among public and private US payers despite health benefits. Health Aff (Millwood). 2011;30(12):2355-2361.
5. Centers for Disease Control and Prevention (CDC). Trends in in-hospital newborn male circumcision - United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2011;60(34):1167-1168.
6. Leibowitz AA, Desmond K, Belin T. Determinants and policy implications of male circumcision in the United States. Am J Public Health. 2009;99(1):138-145.
7. Dave SS, Fenton KA, Mercer CH, Erens B, Wellings K, Johnson AM. Male circumcision in Britain: findings from a national probability sample survey. Sex Transm Infect. 2003;79(6):499-500. (Pubitemid 38021418)
8. Frisch M, Friis S, Kjaer SK, Melbye M. Falling incidence of penis cancer in an uncircumcised population (Denmark 1943-90). BMJ. 1995;311(7018):1471. (Pubitemid 3003934)
9. World Health Organization; Joint United Nations Programme on HIV/AIDS, London School of Hygiene and Tropical Medicine. Male Circumcision: Global Trends and Determinants of Prevalence, Safety, and Acceptability. Geneva, Switzerland: World Health Organization; 2008.
10. Auvert B, Sobngwi-Tambekou J, Cutler E, et al. Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis. 2009;199(1):14-19.
11. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med. 2005;2(11):e298.
12. Bailey RC, Moses S, Parker CB, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet. 2007;369(9562):643-656. (Pubitemid 46281312)
13. Gray RH, Kigozi G, Serwadda D, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet. 2007;369(9562):657-666.
14. Gray RH, Serwadda D, Kong X, et al. Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis. 2010;201(10):1455-1462.
15. Tobian AA, Serwadda D, Quinn TC, et al. Male circumcision for the prevention of HSV-2 and HPV infections and syphilis. N Engl J Med. 2009;360(13):1298-1309.
16. Tobian AA, Kong X, Gravitt PE, et al. Male circumcision and anatomic sites of penile high-risk human papillomavirus in Rakai, Uganda. Int J Cancer. 2011;129(12):2970-2975.
17. Gray RH, Kigozi G, Serwadda D, et al. The effects of male circumcision on female partners' genital tract symptoms and vaginal infections in a randomized trial in Rakai, Uganda. Am J Obstet Gynecol. 2009;200(1):42.-e1-42.e7. doi:10.1016/j.ajog.2008.07.069.
18. Wawer MJ, Tobian AA, Kigozi G, et al. Effect of circumcision of HIV-negative men on transmission of human papillomavirus to HIV-negative women: a randomised trial in Rakai, Uganda. Lancet. 2011;377(9761):209-218.
19. Warner L, Ghanem KG, Newman DR, Macaluso M, Sullivan PS, Erbelding EJ. Male circumcision and risk of HIV infection among heterosexual African American men attending Baltimore sexually transmitted disease clinics. J Infect Dis. 2009;199(1):59-65.
20. Nielson CM, Schiaffino MK, Dunne EF, Salemi JL, Giuliano AR. Associations between male anogenital human papillomavirus infection and circumcision by anatomic site sampled and lifetime number of female sex partners. J Infect Dis. 2009;199(1):7-13.
21. Tobian AA, Gray RH, Quinn TC. Male circumcision for the prevention of acquisition and transmission of sexually transmitted infections: the case for neonatal circumcision. Arch Pediatr Adolesc Med. 2010;164(1):78-84.
22. Larke N, Thomas SL, Dos Santos Silva I, Weiss HA. Male circumcision and human papillomavirus infection in men: a systematic review and meta-analysis. J Infect Dis. 2011;204(9):1375-1390.
23. Schoen EJ, Colby CJ, Ray GT. Newborn circumcision decreases incidence and costs of urinary tract infections during the first year of life. Pediatrics. 2000;105(4, pt 1):789-793. (Pubitemid 30219526)
24. American Academy of Pediatrics, Task Force on Circumcision. Circumcision policy statement. Pediatrics. 1999;103(3):686-693.
25. Wiswell TE, Smith FR, Bass JW. Decreased incidence of urinary tract infections in circumcised male infants. Pediatrics. 1985;75(5):901-903. (Pubitemid 15054323)
26. Chesson HW, Gift TL, Owusu-Edusei K Jr, Tao G, Johnson AP, Kent CK. A brief review of the estimated economic burden of sexually transmitted diseases in the United States: inflation-adjusted updates of previously published cost studies. Sex Transm Dis. 2011;38(10):889-891.
27. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13(4):322-338. (Pubitemid 24013155)
28. Tobian AA, Ssempijja V, Kigozi G, et al. Incident HIV and herpes simplex virus type 2 infection among men in Rakai, Uganda. AIDS. 2009;23(12):1589-1594.
29. Tobian AAR, Charvat B, Ssempijja V, et al. Factors associated with the prevalence and incidence of herpes simplex virus type 2 infection among men in Rakai, Uganda. J Infect Dis. 2009;199(7):945-949.
30. Gold M. Panel on cost-effectiveness in health and medicine. Med Care. 1996;34(12)(suppl):DS197-DS199.
31. Weiss HA, Larke N, Halperin D, Schenker I. Complications of circumcision in male neonates, infants, and children: a systematic review. BMC Urol. 2010;10:2.
32. Schoen EJ, Colby CJ, To TT. Cost analysis of neonatal circumcision in a large health maintenance organization. J Urol. 2006;175(3, pt 1):1111-1115. (Pubitemid 43200107)
33. Centers for Disease Control and Prevention (CDC). Subpopulation estimates from the HIV incidence surveillance system - United States, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(36):985-989.
34. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990-997. (Pubitemid 44674030)
35. Harrison KM, Song R, Zhang X. Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr. 2010;53(1):124-130.
36. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. J Acquir Immune Defic Syndr. 2006;43(4):451-457. (Pubitemid 44737104)
37. Chen RY, Accortt NA, Westfall AO, et al. Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis. 2006;42(7):1003-1010.
38. Hernandez BY, Barnholtz-Sloan J, German RR, et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer. 2008;113(10)(suppl):2883-2891.
39. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-251. (Pubitemid 351213674)
40. Hu D, Goldie S. The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol. 2008;198(5):500.e1-500.e7. doi:10.1016/j.ajog.2008.03.064.
41. Kim JJ, Goldie SJ. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ. 2009;339:b3884. doi:10.1136/bmj.b3884.
42. Gray RH, Wawer MJ, Serwadda D, Kigozi G. The role of male circumcision in the prevention of human papillomavirus and HIV infection. J Infect Dis. 2009;199(1):1-3.
43. Armstrong GL, Schillinger J, Markowitz L, et al. Incidence of herpes simplex virus type 2 infection in the United States. Am J Epidemiol. 2001;153(9):912-920. (Pubitemid 32378626)
44. Chesson HW, Blandford JM, Gift TL, Tao G, Irwin KL. The estimated direct medical cost of sexually transmitted diseases among American youth, 2000. Perspect Sex Reprod Health. 2004;36(1):11-19. (Pubitemid 38252839)
45. Allsworth JE, Peipert JF. Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data. Obstet Gynecol. 2007;109(1):114-120. (Pubitemid 46035517)
46. Koumans EH, Sternberg M, Bruce C, et al. The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis. 2007;34(11):864-869. (Pubitemid 350287499)
47. Carr PL, Rothberg MB, Friedman RH, Felsenstein D, Pliskin JS. "Shotgun" versus sequential testing: cost-effectiveness of diagnostic strategies for vaginitis. J Gen Intern Med. 2005;20(9):793-799. (Pubitemid 41725692)
48. Marrazzo JM. Evolving issues in understanding and treating bacterial vaginosis. Expert Rev Anti Infect Ther. 2004;2(6):913-922. (Pubitemid 39591923)
49. Bradshaw CS, Morton AN, Hocking J, et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis. 2006;193(11):1478-1486. (Pubitemid 43794575)
50. Owusu-Edusei K Jr, Tejani MN, Gift TL, Kent CK, Tao G. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005. Sex Transm Dis. 2009;36(6):395-399.
51. Gray RH, Wawer MJ. Reassessing the hypothesis on STI control for HIV prevention. Lancet. 2008;371(9630):2064-2065. (Pubitemid 351842568)
52. Bachmann LH, Hobbs MM, Sena AC, et al. Trichomonas vaginalis genital infections: progress and challenges. Clin Infect Dis. 2011;53(suppl 3):S160-S172.
53. Millett GA, Flores SA, Marks G, Reed JB, Herbst JH. Circumcision status and risk of HIV and sexually transmitted infections among men who have sex with men: a meta-analysis. JAMA. 2008;300(14):1674-1684.
54. Fisman DN. Projection of the future dimensions and costs of the genital herpes simplex type 2 epidemic in the United States. Sex Transm Dis. 2002;29(10):608-622.
55. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance, 2010. Atlanta, GA: Dept of Health and Human Services; 2011.
56. Singh-Grewal D, Macdessi J, Craig J. Circumcision for the prevention of urinary tract infection in boys: a systematic review of randomised trials and observational studies. Arch Dis Child. 2005;90(8):853-858. (Pubitemid 41081370)
57. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS. 2012;26(5):609-615.
58. Morris BJ, Bailey RC, Klausner JD, et al. Review: a critical evaluation of arguments opposing male circumcision for HIV prevention in developed countries. AIDS Care. 2012. doi:10.1080/09540121.2012.661836.
59. Kigozi G, Lukabwe I, Kagaayi J, et al. Sexual satisfaction of women partners of circumcised men in a randomized trial of male circumcision in Rakai, Uganda. BJU Int. 2009;104(11):1698-1701.
60. Kigozi G, Watya S, Polis CB, et al. The effect of male circumcision on sexual satisfaction and function, results from a randomized trial of male circumcision for human immunodeficiency virus prevention, Rakai, Uganda. BJU Int. 2008;101(1):65-70. (Pubitemid 350233575)
61. Kigozi G, Gray RH, Wawer MJ, et al. The safety of adult male circumcision in HIV-infected and uninfected men in Rakai, Uganda. PLoS Med. 2008;5(6):e116. doi:10.1371/journal.pmed.0050116.
62. Gray R, Kigozi G, Kong X, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study. AIDS. 2012;26(5):609-615.
63. Morris BJ, Waskett JH, Banerjee J, et al. A 'snip' in time: what is the best age to circumcise? BMC Pediatr. 2012;12(1):20.
64. Krieger JN, Mehta SD, Bailey RC, et al. Adult male circumcision: effects on sexual function and sexual satisfaction in Kisumu, Kenya. J Sex Med. 2008;5(11):2610-2622.
65. Morris BJ, Gray RH, Castellsague X, et al. The strong protective effect of circumcision against cancer of the penis. Adv Urol. 2011;2011:812368. doi:10.1155/2011/812368.
66. Alanis MC, Lucidi RS. Neonatal circumcision: a review of the world's oldest and most controversial operation. Obstet Gynecol Surv. 2004;59(5):379-395. (Pubitemid 38525784)
67. Mehta SD, Gaydos C, Maclean I, et al. The effect of medical male circumcision on urogenital Mycoplasma genitalium among men in Kisumu, Kenya. Sex Transm Dis. 2012;39(4):276-280.